REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Nov 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-11-16

Reporting Person: Landry Robert E (EVP Finance CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-16	Common Stock	M	3750	$399.66	Acquired	29736	Direct
2021-11-16	Common Stock	F	3069	$651.97	Disposed	26667	Direct
2021-11-17	Common Stock	S	681	$645.08	Disposed	25986	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-16	Non-Qualified Stock Option (right to buy)	$399.66	M	3750	Disposed	2024-12-16	Common Stock (3750)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	229	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: The stock option award vests in four equal annual installments, commencing one year after the date of grant.